Effect of p53 Activity on the Sensitivity of Human Glioblastoma Cells to PARP-1 Inhibitor in Combination with Topoisomerase I Inhibitor or Radiation(360 views) Sabbatino F, Fusciello C, Somma D, Pacelli R, Poudel R, Pepin D, Leonardi A, Carlomagno C, Della Vittoria Scarpati G, Ferrone S, Pepe S
Cytom Part A (ISSN: 1552-4922), 2014 Nov; 85A(11): 953-961.
Department of Clinical Medicine and SurgeryUniversity of Naples Federico II Via Sergio Pansini 5Naples Italy80131
Department of SurgeryMassachusetts General Hospital, Harvard Medical SchoolBoston, Massachusetts02114
Department of Molecular Medicine Medical BiotechnologyUniversity of Naples Federico IIVia Sergio Pansini 5Naples Italy80131
Department of Biomedical Advanced SciencesUniversity of Naples Federico II Via Sergio Pansini 5Naples Italy80131
Institute of Biostructures and Bioimaging CNRVia Sergio Pansini 5Naples Italy80131
Department of Diagnostic Imaging and Radiation OncologyUniversity of Naples Federico II Via Sergio Pansini 5Naples Italy80131
Faculty of Pharmacy and Medicine Department of MedicineUniversity of SalernoVia S. AllendeBaronissi (Salerno) Italy84131
References: Stupp, R., Mason, W.P., van den Bent, M.J., Weller, M., Fisher, B., Taphoorn, M.J., Belanger, K., Bogdahn, U., Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma (2005) N Engl J Med, 352, pp. 987-99
Ohgaki, H., Dessen, P., Jourde, B., Horstmann, S., Nishikawa, T., Di Patre, P.L., Burkhard, C., Maiorka, P.C., Genetic pathways to glioblastoma: a population-based study (2004) Cancer Res, 64, pp. 6892-6899
Wang, Y., Zhu, S., Cloughesy, T.F., Liau, L.M., Mischel, P.S., p53 disruption profoundly alters the response of human glioblastoma cells to DNA topoisomerase I inhibition (2004) Oncogene, 23, pp. 1283-1290
Sasine, J.P., Feun, L.G., Topoisomerase I inhibitors in the treatment of primary CNS malignancies: An update on recent trends (2011) Anticancer Agents Med Chem, 10, pp. 683-696
Pinel, S., Chastagner, P., Merlin, J.L., Marchal, C., Taghian, A., Barberi-Heyob, M., Topotecan can compensate for protracted radiation treatment time effects in high grade glioma xenografts (2006) J Neurooncol, 76, pp. 31-38
Fisher, B., Won, M., Macdonald, D., Johnson, D.W., Roa, W., Phase II study of topotecan plus cranial radiation for glioblastoma multiforme: Results of Radiation Therapy Oncology Group 9513 (2002) Int J Radiat Oncol Biol Phys, 53, pp. 980-986
Klautke, G., Schutze, M., Bombor, I., Benecke, R., Piek, J., Fietkau, R., Concurrent chemoradiotherapy and adjuvant chemotherapy with Topotecan for patients with glioblastoma multiforme (2006) J Neurooncol, 77, pp. 199-205
Bernier-Chastagner, V., Grill, J., Doz, F., Bracard, S., Gentet, J.C., Marie-Cardine, A., Luporsi, E., Laithier, V., Topotecan as a radiosensitizer in the treatment of children with malignant diffuse brainstem gliomas: results of a French Society of Paediatric Oncology Phase II Study (2005) Cancer, 104, pp. 2792-2797
Gross, M.W., Altscher, R., Brandtner, M., Haeusser-Mischlich, H., Chiricuta, I.C., Siegmann, A.D., Engenhart-Cabillic, R., Open-label simultaneous radio-chemotherapy of glioblastoma multiforme with topotecan in adults (2005) Clin Neurol Neurosurg, 107, pp. 207-213
Grabenbauer, G.G., Gerber, K.D., Ganslandt, O., Richter, A., Klautke, G., Birkmann, J., Meyer, M., Effects of concurrent topotecan and radiation on 6-month progression-free survival in the primary treatment of glioblastoma multiforme (2009) Int J Radiat Oncol Biol Phys, 75, pp. 164-169
Lesimple, T., Riffaud, L., Frappaz, D., Ben Hassel, M., Gedouin, D., Bay, J.O., Linassier, C., Fabbro, M., Topotecan in combination with radiotherapy in unresectable glioblastoma: A phase 2 study (2009) J Neurooncol, 93, pp. 253-260
Ratnam, K., Low, J.A., Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology (2007) Clin Cancer Res, 13, pp. 1383-1388
Wesierska-Gadek, J., Schmid, G., Cerni, C., ADP-ribosylation of wild-type p53 in vitro: Binding of p53 protein to specific p53 consensus sequence prevents its modification (1996) Biochem Biophys Res Commun, 224, pp. 96-102
Simbulan-Rosenthal, C.M., Rosenthal, D.S., Iyer, S., Boulares, A.H., Smulson, M.E., Transient poly(ADP-ribosyl)ation of nuclear proteins and role of poly(ADP-ribose) polymerase in the early stages of apoptosis (1998) J Biol Chem, 273, pp. 13703-13712
Griffin, R.J., Curtin, N.J., Newell, D.R., Golding, B.T., Durkacz, B.W., Calvert, A.H., The role of inhibitors of poly(ADP-ribose) polymerase as resistance-modifying agents in cancer therapy (1995) Biochimie, 77, pp. 408-422
Bowman, K.J., Newell, D.R., Calvert, A.H., Curtin, N.J., Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro (2001) Br J Cancer, 84, pp. 106-112
Tentori, L., Portarena, I., Graziani, G., Potential clinical applications of poly(ADP-ribose) polymerase (PARP) inhibitors (2002) Pharmacol Res, 45, pp. 73-85
Tentori, L., Graziani, G., Chemopotentiation by PARP inhibitors in cancer therapy (2005) Pharmacol Res, 52, pp. 25-33
Cimmino, G., Pepe, S., Laus, G., Chianese, M., Prece, D., Penitente, R., Quesada, P., Poly(ADPR)polymerase-1 signalling of the DNA damage induced by DNA topoisomerase I poison in D54(p53wt) and U251(p53mut) glioblastoma cell lines (2007) Pharmacol Res, 55, pp. 49-56
Sabisz, M., Wesierska-Gadek, J., Skladanowski, A., Increased cytotoxicity of an unusual DNA topoisomerase II inhibitor compound C-1305 toward HeLa cells with downregulated PARP-1 activity results from re-activation of the p53 pathway and modulation of mitotic checkpoints (2010) Biochem Pharmacol, 79, pp. 1387-1397
Bao, S., Wu, Q., McLendon, R.E., Hao, Y., Shi, Q., Hjelmeland, A.B., Dewhirst, M.W., Rich, J.N., Glioma stem cells promote radioresistance by preferential activation of the DNA damage response (2006) Nature, 444, pp. 756-760
Fuxe, J., Akusjarvi, G., Goike, H.M., Roos, G., Collins, V.P., Pettersson, R.F., Adenovirus-mediated overexpression of p15INK4B inhibits human glioma cell growth, induces replicative senescence, and inhibits telomerase activity similarly to p16INK4A (2000) Cell Growth Differ, 11, pp. 373-384
Mosmann, T., Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays (1983) J Immunol Methods, 65, pp. 55-63
Burkle, A., Chen, G., Kupper, J.H., Grube, K., Zeller, W.J., Increased poly(ADP-ribosyl)ation in intact cells by cisplatin treatment (1993) Carcinogenesis, 14, pp. 559-561
Huang, X., Halicka, H.D., Darzynkiewicz, Z., Detection of histone H2AX phosphorylation on Ser-139 as an indicator of DNA damage (DNA double-strand breaks) (2004) Curr Protoc Cytom, 7, p. 27. , Chapter 7
Hao, D.L., Liu, C.M., Dong, W.J., Gong, H., Wu, X.S., Liu, D.P., Liang, C.C., Knockdown of human p53 gene expression in 293-T cells by retroviral vector-mediated short hairpin RNA (2005) Acta Biochim Biophys Sin (Shanghai), 37, pp. 779-783
Sabbatino, F., Wang, Y., Wang, X., Flaherty, K.T., Yu, L., Pepin, D., Scognamiglio, G., Cooper, Z.A., PDGFRalpha up-regulation mediated by sonic hedgehog pathway activation leads to BRAF inhibitor resistance in melanoma cells with BRAF mutation (2014) Oncotarget, 5, pp. 1926-1941
Piroth, M.D., Gagel, B., Pinkawa, M., Stanzel, S., Asadpour, B., Eble, M.J., Postoperative radiotherapy of glioblastoma multiforme: analysis and critical assessment of different treatment strategies and predictive factors (2007) Strahlenther Onkol, 183, pp. 695-702
Durkacz, B.W., Omidiji, O., Gray, D.A., Shall, S., (ADP-ribose)n participates in DNA excision repair (1980) Nature, 283, pp. 593-596
Ueno, A.M., Tanaka, O., Matsudaira, H., Inhibition of gamma-ray dose-rate effects by D2O and inhibitors of poly(ADP-ribose) synthetase in cultured mammalian L5178Y cells (1984) Radiat Res, 98, pp. 574-582
Thraves, P., Mossman, K.L., Brennan, T., Dritschilo, A., Radiosensitization of human fibroblasts by 3-aminobenzamide: an inhibitor of poly(ADP-ribosylation) (1985) Radiat Res, 104, pp. 119-127
Kelland, L.R., Tonkin, K.S., The effect of 3-aminobenzamide in the radiation response of three human cervix carcinoma xenografts (1989) Radiother Oncol, 15, pp. 363-369
Papeo, G., Forte, B., Orsini, P., Perrera, C., Posteri, H., Scolaro, A., Montagnoli, A., Poly(ADP-ribose) polymerase inhibition in cancer therapy: are we close to maturity? (2009) Expert Opin Ther Pat, 19, pp. 1377-1400
Nguewa, P.A., Fuertes, M.A., Alonso, C., Perez, J.M., Pharmacological modulation of Poly(ADP-ribose) polymerase-mediated cell death: exploitation in cancer chemotherapy (2003) Mol Pharmacol, 64, pp. 1007-1014
Pilch, D.R., Sedelnikova, O.A., Redon, C., Celeste, A., Nussenzweig, A., Bonner, W.M., Characteristics of gamma-H2AX foci at DNA double-strand breaks sites (2003) Biochem Cell Biol, 81, pp. 123-129
Banath, J.P., Olive, P.L., Expression of phosphorylated histone H2AX as a surrogate of cell killing by drugs that create DNA double-strand breaks (2003) Cancer Res, 63, pp. 4347-4350
MacPhail, S.H., Banath, J.P., Yu, T.Y., Chu, E.H., Lambur, H., Olive, P.L., Expression of phosphorylated histone H2AX in cultured cell lines following exposure to X-rays (2003) Int J Radiat Biol, 79, pp. 351-358
Takahashi, R., Giannini, C., Sarkaria, J.N., Schroeder, M., Rogers, J., Mastroeni, D., Scrable, H., p53 isoform profiling in glioblastoma and injured brain (2012) Oncogene, 32, pp. 3165-3174
Gorczyca, W., Gong, J., Ardelt, B., Traganos, F., Darzynkiewicz, Z., The cell cycle related differences in susceptibility of HL-60 cells to apoptosis induced by various antitumor agents (1993) Cancer Res, 53, pp. 3186-3192
Martin, S., Janouskova, H., Dontenwill, M., Integrins and p53 pathways in glioblastoma resistance to temozolomide (2012) Front Oncol, 2, p. 157
Pena-Rico, M.A., Calvo-Vidal, M.N., Villalonga-Planells, R., Martinez-Soler, F., Gimenez-Bonafe, P., Navarro-Sabate, A., Tortosa, A., Manzano, A., TP53 induced glycolysis and apoptosis regulator (TIGAR) knockdown results in radiosensitization of glioma cells (2011) Radiother Oncol, 101, pp. 132-139
Puca, R., Nardinocchi, L., Porru, M., Simon, A.J., Rechavi, G., Leonetti, C., Givol, D., D'Orazi, G., Restoring p53 active conformation by zinc increases the response of mutant p53 tumor cells to anticancer drugs (2011) Cell Cycle, 10, pp. 1679-1689
Ruano, Y., Ribalta, T., de Lope, A.R., Campos-Martin, Y., Fiano, C., Perez-Magan, E., Hernandez-Moneo, J.L., Melendez, B., Worse outcome in primary glioblastoma multiforme with concurrent epidermal growth factor receptor and p53 alteration (2009) Am J Clin Pathol, 131, pp. 257-263
Effect of p53 Activity on the Sensitivity of Human Glioblastoma Cells to PARP-1 Inhibitor in Combination with Topoisomerase I Inhibitor or Radiation
Poly (ADP-Ribose) polymerase-1 (PARP-1) is involved in the DNA repairing system by sensing and signaling the presence of DNA damage. Inhibition of PARP-1 is tested in combination with DNA damaging agents such as topoisomerase I inhibitors or ionizing radiations (RT) for the treatment of glioblastoma (GBM). Disruption of p53, widely prevalent in GBMs, plays a major role in DNA repairing system. The current study investigates whether p53 activity has an effect on the sensitivity of human GBM cells to PARP-1 inhibitors in combination with topoisomerase I inhibitor topotecan (TPT) and/or RT. Human GBM cell lines carrying a different functional status of p53 were treated with PARP-1 inhibitor NU1025, in combination with TPT and/or RT. Cytotoxic effects were examined by analyzing the antiproliferative activity, the cell cycle perturbations, and the DNA damage induced by combined treatments. PARP inhibition enhanced the antiproliferative activity, the cell cycle perturbations and the DNA damage induced by both TPT or RT in GBM cells. These effects were influenced by the p53 activity: cells carrying an active p53 were more sensitive to the combination of PARP inhibitor and RT, while cells carrying an inactive p53 displayed a higher sensitivity to the combination of PARP inhibitor and TPT. Our study suggests that p53 activity influences the differential sensitivity of GBM cells to combined treatments of TPT, RT, and PARP inhibitors. (c) 2014 International Society for Advancement of Cytometry
Effect of p53 Activity on the Sensitivity of Human Glioblastoma Cells to PARP-1 Inhibitor in Combination with Topoisomerase I Inhibitor or Radiation